Sunshine Biopharma Inc. (SBFMW) — SEC Filings
Sunshine Biopharma Inc. (SBFMW) — 45 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 27 8-K, 6 10-Q, 3 SC 13G.
View Sunshine Biopharma Inc. on SEC EDGAR
Overview
Sunshine Biopharma Inc. (SBFMW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Sunshine Biopharma Inc. filed an 8-K on December 12, 2025, reporting on a matter submitted to a vote of security holders on December 11, 2025. The company, incorporated in Colorado with its principal executive offices in Fort Lauderdale, FL, is in the pharmaceutical preparations industry.
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 4 bearish, 39 neutral, 2 mixed. The dominant filing sentiment for Sunshine Biopharma Inc. is neutral.
Filing Type Overview
Sunshine Biopharma Inc. (SBFMW) has filed 27 8-K, 6 10-Q, 2 DEF 14A, 2 S-1, 2 10-K, 1 SC 13G/A, 1 10-Q/A, 3 SC 13G, 1 S-1/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of SBFMW's 39 recent filings, 4 were flagged as high-risk, 17 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $27.73M |
| Net Income | ($3.83M) |
| EPS | ($0.98) |
| Debt-to-Equity | 0.30 |
| Cash Position | $9.31M |
| Operating Margin | -16.0% |
| Total Assets | $31.49M |
| Total Debt | $7.29M |
Key Executives
- Mr. Malek Chamoun
- Dr. Steve N. Slilaty
- Malek Chamoun
- Camille Sebaaly
- Dr. Abderrazzak Merzouki
- Dr. Andrew Keller
- Gregory Sichenzia, Esq.
- Jeff Cahlon, Esq.
Industry Context
Sunshine Biopharma operates in the pharmaceutical sector, with a dual focus on generic prescription drugs in Canada and the development of proprietary drugs. The Canadian generic drug market is influenced by government pricing negotiations and reimbursement policies, as seen with the pCPA. The proprietary drug segment involves high-risk, high-reward R&D for novel treatments in areas like oncology and infectious diseases.
Top Tags
corporate-governance (7) · 8-K (6) · financial-reporting (6) · 10-Q (5) · financials (5) · corporate-action (5) · shareholder-vote (4) · 8-k (4) · filing (4) · sec-filing (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-41282 | Identifies the company's SEC filing history |
| IRS Employer Identification Number | 20-5566275 | Tax identification for the company |
| Revenue | $27.73M | Increased from $25.28M in 2024 for the nine months ended September 30, 2025 |
| Net Loss | $3.83M | Increased from $2.98M in 2024 for the nine months ended September 30, 2025 |
| Impairment of intangible assets | $1.62M | Recorded for the nine months ended September 30, 2025, compared to $0 in 2024 |
| Cash and cash equivalents | $9.31M | Decreased from $9.69M at December 31, 2024 |
| Accumulated Deficit | $72.87M | As of September 30, 2025, indicating significant historical losses |
| Net proceeds from public offering | $1.83M | Received on April 3, 2025 |
| Common shares outstanding | 4,905,945 | As of November 13, 2025 |
| Remaining earnout payable | $295,797 | In dispute with former Nora Pharma seller Mr. Malek Chamoun |
| Revenue growth | 9.7% | For the nine months ended September 30, 2025, compared to 2024 |
| Gross profit | $9.23M | Increased from $7.58M in 2024 for the nine months ended September 30, 2025 |
| Shares authorized for 2023 Equity Incentive Plan | 683,000 | Proposed increase in shares for issuance |
| Series B Preferred Stock shares outstanding | 130,000 | Each share has 1,000 votes, all held by CEO |
| Votes per Series B Preferred Stock share | 1,000 | Significantly amplifies CEO's voting power |
Forward-Looking Statements
- {"claim":"Sunshine Biopharma will release further details about the material definitive agreement.","entity":"Sunshine Biopharma, Inc.","targetDate":"2024-03-15","confidence":"high"}
- {"claim":"Sunshine Biopharma will likely engage in further capital-raising activities, potentially involving the newly updated share classes.","entity":"Sunshine Biopharma, Inc.","targetDate":"within 6-12 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sunshine Biopharma Inc. (SBFMW)?
Sunshine Biopharma Inc. has 45 recent SEC filings from Jan 2024 to Dec 2025, including 27 8-K, 6 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SBFMW filings?
Across 45 filings, the sentiment breakdown is: 4 bearish, 39 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Sunshine Biopharma Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sunshine Biopharma Inc. (SBFMW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sunshine Biopharma Inc.?
Key financial highlights from Sunshine Biopharma Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SBFMW?
The investment thesis for SBFMW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sunshine Biopharma Inc.?
Key executives identified across Sunshine Biopharma Inc.'s filings include Mr. Malek Chamoun, Dr. Steve N. Slilaty, Malek Chamoun, Camille Sebaaly, Dr. Abderrazzak Merzouki and 3 others.
What are the main risk factors for Sunshine Biopharma Inc. stock?
Of SBFMW's 39 assessed filings, 4 were flagged high-risk, 17 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Sunshine Biopharma Inc.?
Recent forward-looking statements from Sunshine Biopharma Inc. include guidance on {"claim":"Sunshine Biopharma will release further details about the material definitive agreement.","entity":"Sunshine B and 1 other predictions.